Trial Profile
Phase 1 study of cenicriviroc in combination with evogliptin in healthy adult subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2016
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary) ; Evogliptin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- 01 Nov 2016 This trial was conducted by Tobira Therapeutics which has now acquired by Allergan according to a Allergan media release.
- 12 Sep 2016 Status changed from planning to recruiting, as reported in a Tobira Therapeutics media release.
- 13 Apr 2016 New trial record